Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-020 vs MabThera in indolent non-Hodgkin's lymphoma
NCT01701232Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Sep 2011
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of IBI301 in follicular lymphoma (FL), nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), sponsored by BIOCAD. Started Sep 2011; status: completed.
02
Drugs
IBI301
03
Conditions
follicular lymphoma (FL)nodal marginal zone lymphoma (NMZL)splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on NCT01701232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01701232.